Hosted on MSN1mon
Regeneron projects EYLEA HD growth with new approvals and prefilled syringe launch in 2025CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA HD uptake expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback